REGISTERED COMPANY NUMBER: 05017662 IEn8land and Wales)
REGISTERED CHARrrY NUMBEA: 1106320
Re
olthe Trustees and
Unau
Flnanclal Ststements for the Year Endèd 31 December 2023
for
THE BRITISH ASSOCIAnON FOR THE STUDY OF
THE LIVER
A COMPANY LIMITED BY GuARATr￿EE
Elsby & Co Isywelll Ltd
Chartered Ac¢ountsnts
155 Welllngborough Road
Rushden
Northamptonshife
NNIO 9TB

SH
oci
THE LIV
Conten
for the
h FlnancFal Statemen
r ende
I DECEMBER 20
Pale
Report of the Trustees
I to 5
Independent Examlner's Report
Statement of Flnandal Adl¥ltl@s
Balance Sheet
Cash Flow Ststement
io
Notes to the Cash Flow Ststement
li
Notes to the Flnanclal Statements
12 to 18
Detalled Statement of Flnandal ArtlvltSes
19

E8RI
CIATION FO
THE UV
THE
DY
ort of the Tru
ear ended 310E
es
rthe
EMBER 202
The trustees who are also dlrectors of the charity for the purposes of the Companies Act 2006, present thelr report
with the financlal statements of the charity for the year ended 31 December 2023. The trustees have adopted the
provisions of Accounting and Reporting by Charitie5.' Statement of Recommended Practice applicable to charlties
preparlng their account5 In accordance with the Financial Reportlng Standard applicable in the UK and Republic of
Irèland IFRS 1021 (effectivè l January 20191.
The financial statements have been prepared in accordance with the accounting policSes set out in notes to the
accounts and comply with the charity's 8overning document, the Charities Act 2011 and Accounting and Reportlng by
Charities.. Statement of Recommended Practice applicable to charities preparing their accounts in accordance wlth the
Flnanclal Reporting Standard applicable in the UK and Republic of Ireland published on 16 July 2014 la5 amended by
Update Bulletin I published on 2 February 20161.
oBJE￿IVEs AND AcnvmES
Oblectlve$ and alms
The objectives of the company, as Set out in the Memorandum of AssocSatSon as amended by Special Resolution. are
to advance education and awareness in liver disease and disorder, by the provision or the facilitation of research
directed towards the development and evaluation of treatment of such disease and disorders. The trustees confirm
that they have referred to the guSdan¢e contained in the Charity Cornmi55ion's guidance on public benefit when
reviewing the associatiori'5 aims and objectives and In plannlng future activitie5.
The Trustees carry out these objecls by..
Having educational meetings for medical professionals to attend to further theii knowledge and advance education.
awareness and research into liver disease.
Supportin8 special interest groups to further education of specific areas of liver disease.
To asses5 success in the reporting period, BASL aim to maintain and increase membership, provide educational events-
predominantly the Annual Scientific Meeting. To maintain Sufficient funds to allow these activities to take place.
Contrlbutlon
The £ontributlon of eath Inember 55 lin)Ited to £1 In tl)e eveiii uf4 disxjlution of the Company.
Page I

THE BRMSH ASSO
IATION F
THE LIVER
R ThE ¥niDYOF
Re
ort of the Trvstees
ear ended
I DECEMBER 20
for the
sfRATEGIC REPORT
Achlevement and performan
Charmable actlvltlès
BASL Annual Meetlng Ilncorporatlng the annual BTLG and BLNA meetln81
The 2023 BASL Annual meetin8 was held at the DoubleTree Metropole in Brlghton and proved to be a great success
providin8 Int•raction and learning opportunStlC&. Thcrc wcrc 639 dcle88tes across all three rneet1n￿ whlch made an
ex¢ellent surplus. The Sheila Sherlock priie went to Dr Kushala Abeysekera and Dr Oliver Tavable received the Andrew
8urrou8hs Young Investigator award.
BASL Schools
ÈASL Schools are small 8roup meètln8s provlded free of charge to tralnee members In Gastroenterolo8y and
Hepatology that deliver structured education and interactlon with experts in the field. These help the ¢harity to meet
Its objertives by committing to improving clinical education and training for tomorrow's Hepatology Consultants,
Trainees inteTested in transplantatTon and anaesthesia.
These were held as 6 Interactive Weblnars. These proved to be a great success and feedback wa5 excellent.
BASL Xtra
Thi5 is an online educational conference and was the second one io be held. This a multi-profe5sional, topic focused
educatlonal online event. Attendance and surplus were excellent and the decision wa5 made to continue to hold thls
event annually.
BASL Introductlon to Hepatolo8y Day
The meeting was held in Birmingham. This wa5 deemed to be a great 5ucce5s and provided a small surplus.
BVHG Meetln85'
Two meetlngs were held in 2023 due to the 2022 meetlng being delayed unt51 January 2023. These meetlngs were
very popular and provlded an excellent surplus.
BASL 8asSc Sclence Retreat
Thls was held in London and any shortfall was covered by the Institute of Hepatology. who organised the event on
behalf of BASL. Thls was very popular and well attended.
5pectal Irrterest Groups
BASL provides ongoing admlnlstratlve support to a number of established Special Interest Groups ISIGS) whose remit
Is to promote and encourage ¢ollaborative research and clinleal tfials in liver disease.
HCC-UK Annual Meetlng
This was held at the Royal College of Physlclans In Edinburgh. This wa5 very well attended and mède an excellent.
surplus
CCA-UK Annual Meetlng
This was held in Nottingham and made a significant deficlt. Changes were made to future format for this meeting to
prevent more deficit.
BAAL
This was ihe first meeting tor thls newly formed 8foupi held In Birmingham. Costs were covered and a small surplus
was made.
BHPG Educatlonal Meetlng
Meetings were held in Febmary and November In 2023 and a good surplus was made due to good sponsorship belng
achieved.
Secretsrlat
Secretariat servir.es were provlded by Executive Bvslrtess Support Ltd.
Page 2

Rm
OCIAfoN
THE LIVER
R THEsfuDY
ort of th Trustees
nded 310ECEMBEK2023
for th
ear
TO ensure a balanced picture of the charity's progress against its objectives, sufficient funds are rnalntained to allow
the Desired educational events held to continue to take place.
The key performance Inditators to explaln outputs achleved by activities are the level and number5 of members
Ini1¥651n& as well as rnalnialnlng (Jelegate member5 at edu¢ationai events.
Flnanclal revlew
Flnandal posltlon
Detailed finance reports are produced for the Tiuslee5 for every gove¥nln8 board meeElng. The Trusiees aim io
achSeve a Surplus or Breakeven for every Èducatlonal meeting. The results for the year are shown on page 16. The
trustees alm to hold sufficient reserves to support key rneetings in the event of potential shortfalls in income. The
membership and subscriptions database has been updated and clarified and the charity currently ha5 1,624 12022..
1,4231 active members. The BASL website continued to provide a good platform for providing news and information as
well as serving as an interactive communications and education hub for rnembers.
The ¢harity managed to athieve incorne of £533,53912022'. E397,8921 during the year.
Cash reserves have been stable at £261,21012022'. £206,737) due to the charlty continuing to hold events on a virtual
basis, as well a5 face to face. resulting in lower costs as a result and in addition, increasin8 membership fees.
The trusteès believe that the charlty has suffieient reserves to continue and hopes to achieve a greater surplus in 2024
with the aim of holding events on a face to face basi5. as well as some on a virtual basis. The charity always hopes to
retain reserves in unrestricted funds to cover 24 months operational costs and at the end of the accountin8 period,
these had decreased to £173.61512022.. £125.0011. It is hoped that reserves will return to forrner levels over the ne¥t
¥0 years and be able to cover 24 months of operatinnal rngts during the 2024 and 2025 atcountin8 periods.
Significant events that have affected financial performance and financial position during the pèritsd, include an
Increase in fa¢e to face meetings held, followin8 more virtual event5 durin8 2020 2022 due to Covid. This resulted in
an increase In ¢osts to hold meetings as well as increased sponsorship and delÈeatp. inc.nmp fiose atténtion is made
to ensure all events held make a surplus or at the very least cost neutral. Factor5 likely to affect future financial
performance or position are the advancement in medical science resulting in an intrease in education of the members
and potential increase In sponsorship from Pharmaceutical companies to promote new treatments. Principal funding
sources are the membership income as well as sponsorship from Pharmaceutical ¢omDanies and delÉ*gxte incom
from events.
ReseNes poll¢y
Reserves are needed as sponsorship by PharmaceutScal companies of educational events. which are one of the kp.y
objectives Of BASL, can drop suddenly depending on the current fo¢u5 of the Pharmaceutical Companie5. As stated in
the Articles of Association.. The Association will airn to retain sufficient capital funds in Teserve to permit it to conduct
its activities as defined by the Governing Board for a period of years in the absence of any incorne over this
peflod.
Future Developments
The Trustees airn to continue to provide educational meetings and other member benefits In accordance with the
objectives of the Charity. The experience of the pandemlc has resulted in the ability to run meetings on a virtual basls
to ensure events still takè place. making meetSngs accessible to members and meanlng external risk factors are more
manageable.
srRucfuRE, GOVERNANCE ANO MANAGEMENT
Govemlng document
The charity is controlled by Its 8overnln8 document, a deed of trust, and constitutes a Ilmited company, limited bv
guarantee. as defined by the Companies Act 2006.
Page 3

E BR
ASSOCIAn
THE LIVER
RTHE
Re
ort of the Tr
ear ended 31 DECEMBER 20
ee
for the
STrUCWRE. GOVERNANCE AND MANAGEMENT
Induttlon and tralnln8 of new trustee5
Newly elerted trvstees attend quarterly meetings wlth the Chairperson and the governlng board to observe the
provlslon of services to member5. They are also 8lven 8uidance which include an outllne of thelr role and a handover
from the out8olng Trustee.
The charfty makes decisions through it's governing board. Pollcles and pro¢edures for Induction and tralning of
trustees Is supported by the current and outgoing Trustees.
REFERENCE AND ADMINisfRATIVE D￿AlL5
Re8lstered Company number
05017662 (England and Wale51
Re815tered Charlty number
1106320
ReBlstered offi
Executive Business Support
Da￿dSOn Road
Ll¢hfield
Staffordshire
WS14 9DZ
Trustees
Dr TJ S Cross Consultant Hepatologist lappolnted 22.9.231
Professor B R Davidson Hepatobiliary and Transplant Consultant Iresigned 22.9.231
Dr TJ Kendall Senior Clinical Fellow In Pathology
Dr l A C Rowe University Clinical Academic Fellow
Dr V_qnnwdon Consijltant HÈpatolo8i5t
M5 M B Clayton Lecturer In Liver Care
Dr M A Afdersley Consultant Hepatologi5t Ires18ned 1.2.231
Dr K J Simpson Consultant Physician and Senior Le¢tiJrer (resigned l.10.231
Profe5$0r M E Cramp Consultant Hepatologist
Dr A M Elsharkawy Consultant Hepatolosist
Dr R Jones Consultant Hepatologist (resigned 22.9.231
Dr K Drysale Hepatolgy Registrar Clinical Research IrÈsigned 31.1.231
Professor R Mookerjee Professor of Translational Hepatology
Dr M Allison Consultant Hepatolo8lSt
Dr S Chokshi Acting Director & Chief Scientific Offic
Dr O A A Elshaarawy lappointed 18.5.231
Professor P Kennedy Consultant Hepatologtst and Gastroentero (appointed 30.1.231
Mrj A Flichard Doctor (appointed 31.10.231
Independent Examlner
Carl Elsby AfA
Elsby & Co Isywelll Ltd
Chartered Accountants
155 W¥llin¥bort)u¥h Rodd
Rushden
Northamptonshire
NNIO 9TB
Pase 4

CIATION FOR TH
THE UVER
he Trustees
ar ended 310ECEMBER 2
for
Report of the trustees. Incorporating a strateglc report. approved by order of the board of irustees, as the tompany
dlrertors, on .......
J.*J..:..k2kg*.......... and signed on the board's behalf bv..
Dr
M Elsharkawy- Trustee
Page 5

Inde
end
Examlner's R
The Brltlsh Assoclatlon for the S
the Llve
ees of
Independent examlner's report to the trustees of The 8rltlsh Assoclatlon for the Study of the Uver I'the Companv'l
I report to ihe charity trustees on my examination of ihe accounts of the Company for the year ended
31 December 2023.
RÈsponslbllltl•s and bas1$ of report
s the charlty'5 trustee5 of the Company land also Its dlrectors for the purposes of company lawl you are responsible
for ihe preparation of the accounts in accordance with the requlrernents of the Cornpanles Act 20061'the 2006 Act'l.
Hawng 5at15fied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act
and are ell￿ble for independent examination, I report In respect of my examination of your charity's accounts as
¢arried out undef Section 145 of the Charitles Act 2011 I'the 2011 Aet'l. In carrying out my exarnlr¥aiion I have
followed the Direction5 8iven by the Charlty Cornmission under Sectlon 145151 Ibl of the 2011 Act.
Independent examlner's statement
Since your charity's gross income exceeded £250,000 your examlnei must be a member of a listed body. I can confirm
that l am qualified to undertake the examinatSon because l am a member of the Institute of Chartered Accountants In
England and Wales. which is one of the Ilsted bodies.
I have completed my examlnatlon. I confirm that no matters have come to my attention Sn connectlon with the
examination 8ivlng me cause to believe..
accovntlng re¢ord5 were not kept In resped of the Company as requlred by Section 386 of the 2006 Act,. or
the accounts do not accord wlth those re¢ord5,' or
the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any
Tequirement that the accounts glve a true and fair view whlch is not a matter considered as part of an
independent examlnatlon; or
thè accounts have not been prepared in accordance wlth the methods and principles of the Statement of
Recommended Practice for accounttng and reportlng by charities (applicable to charitles preparing their
accounts In accordance with the Financlal Reporting Standard applicable in the UK and Republic of Ireland IFRS
10211.
I have no concerns and have come across no other matters in connertion with ihe examination to which attention
should be drawn in thi5 report In order to enable a proper under5tandlng of rhe accounts to be reached.
Carl Elsby ACA
Elsby & Co Isywelll Ltd
Chartered Accountants
155 Welllngborough Road
Rushden
Northampton5hire
NNIO 9TB
Date..
I st October 2024
Page 6

E8R
IATION F
THE UVER
atem
nt of Flnan
ttlvltl
ear ended 31 DECÈMBER 202
for
2023
Total
funds
2022
Total
funds
Unrestrlcted
funds
Restrltted
funds
Notes
INCOME AND ENDOWMENTS FROM
Mèmbership subscriptlons
116,383
116,383
99.160
conferen￿ fees & sponsorshlp Income
Interest recelvablè
413,049
4,107
413.049
4.107
297,904 1
828
397.892
Total
533,539
533,539
EXPENDtruRE ON
Conference costs
Dirett conference costs
Other associated conference costs
287,534
189,113
287,534
189.113
206,048
197,398
476,647
476.647
403.446
Other
9.014
9.014
13,476
416.922
Totsl
485.661
485.661
NEf INCOMEIIEXPENDfwREI
47,878
47.878
119,0301
RECONCIUATION OF FUNDS
Total funds brought forward
125,001
22,377
147,378
166.408 ',
TOTAL FUNDS CARRIED FORWARD
172.879
22,377
195.256
147,378
CONTINUING OPEKATIONS
All income and expenditure has arlsen from contirtulng activities.
The notes form part of these financlal statements
Page 7

THE BRMSH A550CIATION FOR THE STUDY OF
THE LIVER
Balance Shee
31 DECEMBER 2023
2023
Total
fund5
2022
Total
funds
Unrestricted
funds
Restricted
fund5
Note5
FIXED A55Efs
Investments
12
CURRENT ASSETS
Debtors.. amount5 fallin8 due wlthln one year
Cash at bank
13
40,753
238,833
40,753
261,210
17,893
206,737
22.377
279,586
22,377
301.963
224,630
CREOITORS
Amounts falling due wSthln one year
14
169,9261
169.9261
145,1291
NET CURRENT ASSETS
209,660
22,377
232.037
179.501
TOTALASSEfs LESS CURRENT UABiunES
209,661
22.377
232,038
179,502
CREDITORS
Amounts fallirb8 due after more than one year
15
136,7821
136.7821
132,1241
NEfASSErs
172,879
22,377
195,256
147,378
FUNDS
Unrestrl￿ed fitnds..
General fund
Restricied funds..
BASL nurses fund
CCA UK Nell Blenkinsop donatlon for research
only
16
172,879
125,001
6,627
15,750
6.627
15,750
22,377
22,377
TOTAL FUN05
195,256
147.378
The charltable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year
ended 31 December 2023.
The mernbers have not required the Company to obtaln an audit of Sts finantial staternents for the year ended
31 December 2023 in accordance with Section 476 of the Companies Act 2006.
The note5 form part of these financlal statements
Pagè 8
contlfiued..

BRMSH
NFOR
THE UV
Balance sheet. contl
31 DECEMBÉR
The trustees aeknowled8e thelr responslbilities for
ensurSng that the charitable company keeps a¢¢ountSng records that comply wilh Sectlons 386 and 387 of the
Companies Act 2006 and
preparinR ftnancial statements whlch give a true and fair vlew of the state of affalrs of the charltable company
as at the end of each financial year and of its surplus or defi¢lt for each financial year in ac¢ordance with the
requlrements of Sections 394 and 395 and whlch otheTwSse comply with the requirements of the Companies
Ad 2CKJ6 relating to financial statements, so far as appllcable to the charStable company.
Ibl
hnanclal staternents were approved by the Board ol Trustees and aurhorlsed for 155ue
and were signed on Its behalf by..
on
sharkawy- Trusiee
The notes form part of these finan¢lal stst4m•nts
Page 9

ThEBR
H ASSOCI
N FOR THE miDY OF
THE LIVE
Ca h Flow Sta
ar end
31 DECEMO
ern
for the
R 2023
2023
2022
Notes
Cash flow5 from opÈratln8 actlvltles
Cash 8enerated from operations
50.366
15,4491
Net cash provlded byllused Inl operating activltles
50,366
15,4491
sh flows from Investln8 actlvltles
Interest received
4,107
828
Net cash provlded by Snvesting activitles
4,107
828
Change In cash and cash equl¥alents In the
reportln8 perlod
Cash and cash equlvalents at the be8lnnlrbB
of thè reportln8 perlod
54.473
14,6211
206,737
211,358
Cash and cash ÈqulvèlÈnts at the end of
the reportln8 perlod
261,210
206,737
The notes form part of these flnanclal statements
Pa8e 10

E BRMSH
IATION FOR TH
THE UVER
DY
e5 to the Cash Flow Stateme
for the
ear ended 31 DECEMBER 2
RECONCIUATION OF NET INCOME/IEXPENDmJAEI TO NET CASH FLOW FROM OPERATING AcnvtriES
2023
2022
Net Incomellexpendlturel for the reportlng perlod las per ihe
Statement of Flnanclal Acllvltles)
AdJu5tmertts for:
Interest received
Increase in debtors
Increase in creditors
47,878
119,0301
14,1071
122,8601
29,455
18281
13.4291
17,838
Net cash prnvlded byllused Inl operatlons
50,366
15.4491
ANALYSIS OF CHANGES IN NET FUNDS
At 1.1.23
Cash flow
At 31.12.23
Net cash
Cash at bank
206,737
54.473
261.210
. 206,737
54.473
261.210
Total
206,737
54.473
261,210
The notes form part of these financial statements
Page 11

THE 8RITIS
CIATI
THE LIVER
RTH
OF
Not
for the
s to the flnandal 5t tem
ar ended 31 DECEMBER 20
ACCOUPlllNG POUCIE5
General Inforniatlon
The charity Is a private company Ilmlted by guarantee, registered in England and Wale5 and a reglstered
charity In England and Wales. The address of the re8lStered office Is Executlve Business Support, Davidson
Road, Llchfleld. Staffordshire, En8land, WS14 9DZ.
Ba515 of preparlng the financlal statement5
The fin8nei81 statements of the charltable companyi whleh Is a publlc beneflt entity under FRS 102. h3V@ b@en
prepared in accordance with the Charliles SORP IFRS 1021 'Accountln8 and Reportlng by Charities.. Statement
of Recommended Practice appll¢able to eharltles preparlng thelr accounts in accordan¢e with the Flnancial
Reportin8 Standard applicable in the UK and Republic of Ireland IFRS 1021 (effective l January 20191,, Flnanclal
Reporting Standard 102 'The Financlal Reportlng Standard appllcable In the UK and Republic of Ireland, and the
Companies Act 2006. The finaneial statements have been prepared under the historlcal cost convention, with
the exception of investments whlch are Inclyded at market value.
The presentational currency of BASL Is consldered to be pounds sterlin8 and the financial statements are
rounded to the nearest pound.
Incomln8 resou￿@S
All income is recognised In the Statement of Flnanclal Activities once the charlty has entitlement to the funds,
It IS Probable that the Income wlll be recelvéd and the amount can be measured reliablv.
Income recelved for a specific restrlcted purpose Is credited to a separate restrlcted fund whlch Is shown in a
note lo the financlal statements. Total Incomlng resources credited to restrlcted funds are di5¢10sed on the
statement of financial activities whlch a150 show5 incorninB resources in respect of unre5tTlCted funds.
Conferente income represents fees and sponsorshlp received in re5pert of conference'5 or8anised in pursult of
the company's charitable objective5.
Income assoclated wSth conferences of future accounting perlods Is treated as deferred income.
Resources expended
Liabilities are recognised as expendlture as soon as there 15 a legal or constructlve obligation committing the
charity to that expenditure. it 15 probable that a transfer of economi¢ benefits will be required in settlement
and the amount of the obligation can be measured reliably. Where costs cannot be directly attributed to
partiriJl?r hpadin8E thpy hxvp heen allocated to artlvities on a basis consistent with the use of resources.
Resources expended are included In the statement of financial activltles on an accrual basis exclvsive of VAT.
I Irrecovefable VAT is charged against the category of resource5 expended for which it was incurred.
Taxatlon
The activities of the charity are exempt from Corporation Tax under Section 505 of the Income and
Corporatlon Trxe5 Aa 1988 IQ the extent that ihey are applled to the organisaiion'5 charitable objects.
Fund accountlng
Unrestricted funds are donation5 and other incoming resources received or generated for the general
charltable purposes of the charity.
Within unrestricted funds are deslRnated Tunds. The nature of each of the de5iBnated fund% is referred to
within the report of the trustees.
Restricted funds can only be used for paitlcular restricted purposes within the objects of the ¢harlty.
Restrirtions arise when specified by the donor or when funds are ralsed for particular restricted purpose5.
Page 12
contlnued...

THE
MSHAS
IATION FOR THE
THE LIVER
Notes to the Flnan
atements- contlnu
for the
ear ended 31 DECEMBER 2023
ACCOUNTING POLICIES- contlnued
Debtors and creditors
Short term debtors are measured at transaction price (which is usually the invoice pricel, less any Impairrnent
lossès for bad and doubrful debts. Loans and other financial assets are initialSy recognised at transaction price
Including any tran5a¢tion costs and subsequently measured at amortised cost determined usin8 the effective
interest method, legs any impairment losses for bad 3nd doubtful debts.
Short term creditors are measured at transactlon prlce Iwhlch Is usually the invoice pricel. Loans and other
financial liabilities are initially recoBnised at transaction price net of any transaction costs and subsequently
measured at arnortised cost dete¥mlned usln8 the effective interest method.
Cash and cash equlvalents
Cash and cash equivalents include cash In hand and deposits held at call with banks.
CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY
In preparin8 the financial statements It is rtecessary to make ¢ertain judgements, estirnates and assumptions
that affect the amounts retognised int he financial staternents.
In the view of the trustees in applyin8 the accounting policies adopted, no judgements were required that have
Sl8nificant @ffect on the amounts re¢o8nised in the fin3n¢ial statements nor do any estimatès or assumptions
made carry a significant risk of material adjustment in the next financial year.
MEMBERSHIP SUBSCRIPTIONS
2023
2022
Grants
Subs¢ription5
12,729
103,654
99.160
116,383
99.160
Grants receivable are credited to the Statement of Fin3ncial Activtiies ISOFAI in the year for the year for which
they are received. Deferred income represents amounts received for future periods an dis Teleased to incomlng
resources in the period for which it has been received.
CONFERENCE FEES & SPONSORSHIP INCOME
2023
2022
Conference income
413,049
297,904
Page 13
continued,-.

BR
CIATION FOR THE STUDY
THE UVER
Note5
h Mnanclal
atements. contlnued
for the
nded 31 DEC
MBER 2
INTEREST RECEIVABLE
2023
2022
InteTe5t receivable
4,107
828
DIREcf CONFERENCE COSTS
2023
2022
Annual conference costs
Annual 5UPPOrt to UKLA
274,284
13,250
194.548
ii.soo
287,534
206,048
MER ASSOCIATED CONFERENCE Cosrs
2023
2022
Travel & hotels
ArtworVdesi8n & prlnt
CPD application
Bank charges
Website
Secretarial support costs
EBS Costs
Partial exemptlon input VAT
12,511
4.216
956
5,282
4,408
8.044
170,635
116,9391
2,242
3.536
4,196
6,185
5,751
175,204
189.113
197,398
SUPPORT COSTS
Governance
costs
Other resources expended
9.014
INCOMEIIEXPENDtruRE)
Net incomellexpendlturel is stated after charginyJlcTeditingl'.
2023
2022
A￿OUntanCY fees
5,012
5.047
Page 14
continued...

ThEBR
SH
OCIATION FOR THE STUDY OF
THE UVER
t@s tD tho Fln3nclal
for the
ar
-to
ded 31 DECE
BER 20Z3
io.
TRUSTEES, REMUNERATION AND BENEFITS
No trustees recelved any remuneiation durlng the current or prior year.
Trustees, expenses
Travel and speaker expenses totalling E525.3612022.. £728.30) were relmbursed to 412022. 41 trustees during
the year.
ii.
COMPAPATIVES FOR THE STATEMENT OF FINANCIAL AcnviTIES
Unrestricted
funds
Restricted
funds
Total
funds
INCOME AND ENDOWMENTS FROM
MembershÉp subs¢riDtions
99.160
99.160
Conferènce fees & Sponsorship income
Interest receivable
297,904
828
297,904
828
Total
397,892
397,892
EXPENDITURE ON
Conference tosts
Direct Conference costs
Other assoclated conference costs
206.048
197,398
206,048
197,398
403.446
403.446
Other
13,476
13,476
Total
416,922
416.922
NET INCOME/IEXPENDITUREI
119.0301
119,0301
RECONCIUATION OF FUNDS
Total funds brought forward
144.031
22,377
166,408
TOTAL FUNDS CARRIED FORWARD
125,001
22.377
147.378
Page 15
continued...

BRMS
IATI
THE LIVER
THE
DYOF
es to th Flnanclal Stateme
- contlnu
for the
ar ended 31 DECEMBER 202
FIXED ASSEf INVESfMETr￿S
Unllsted
Investments
mARK￿VALuE
At l January 2023 and 31 December 2023
NEf BOOK VALUF
At 31 December 2023
At 31 December 2022
There were no Investment assets outside the UK.
DEBTORS: AMOUNTS FALLING DUE WIThIN ONE YEAR
2023
2022
Trade debtors
Prepayments
32,418
8,335
17,51XI
393
40,753
17,893
14.
cRED￿oRS. AMOUNTS FALLING DUE WITHIN ONE YEAR
Dthrred Income
2023
2022
Deferred Income at l January 2022
Resource5 deferred during the year
Amounts released from prior year
23,000
23,780
I23,Oc￿lI
14.000
23,000
114,(MXJI
Deferre(I Income at 31 December 2022
23,780
23.CQO
Deferred income relates to income received In the year speclffically relatlft8 to performance conditions to be
met in the following year.
Page 16
continued...

THE BRITISH
SOCIATION FOR THE STUDY
THE LIVER
Note
to the Fln
nclal Statements- contlnued
for the
ar ended 31 DECEMBER 2
15.
CREDMRS: AMOUNTS FALUNG DUE AFTER MORE THAN ONE YEAR
2023
2022
Bursary Fund- support for members to attend meetlngs
Swansea health economics work to accompany HCCUK Projec
BLNA restricted fund
24.303
20.381
17361
12,479
12.479
36,782
32,124
16.
MOVEMENTIN FUNDS
Net
movement
in funds
At
31.12.23
At 1.1.23
Unrestrlttèd funds
General fund
125,001
47,878
172,879
Restrlcted funds
BASL nurses fund
CCA UK Neil Blenkinsop donation for
Tesear¢h only
6.627
6,627
15.750
15.750
22.377
22,377
TOTAL FUNDS
147,378
47,878
195,256
Net movement in funds, included in the above are as follows:
Incoming
resources
Resources
expended
Movement
in funds
Unrestrirted funds
Genefal fvnd
533,539
1485,6611
47,878
TOTAL FUNDS
533.539
1485,6611
47.878
page 17
ontlnued...

THE BRMSH
CIAn
FOR
THE LIVER
UDY OF
Note
t the Flnanclal S
for the
ear ended
ents- contlnu
I DECEMBER 202
16.
MOVEMENT IN FUNDS- contlnued
CDmparatlve5 for movement In funds
Net
movement
In funds
At
31.12.22
At 1.1.22
Unrestrl¢ted funds
General fund
144,031
119,0301
125.001
RÈstrlrted fvnds
BASL nurse5 fund
CCA UK Neil Blenklnsop donation for
research onlv
6,627
6,627
15,750
15,750
22,377
22,377
TOTAL FUNDS
166.408
119,0301
147,378
Comparatlve net movemènt in funds. Included In the above are as follows:
Incomrft8
resources
Resources
expended
Movernent
In fund5
Unre5trfrted funds
General fufid
397,892
1416,9221
119,0301
TOTAL FUNDS
397.892
1416.9221
119,0301
17.
RELATED PARTY DISCLOSURES
There were no related party transaction5 for the year ended 31 December 2023.
Pa8e 18

BRrrisH
OCIA
THE LIVER.
THE
DY
alled
or the
atement f F
al A Ivlties
ear en
ed 31 DECEMBER 2023
2023
2022
INCOME AND ENOOWMENTS
Membershlp subscrlptlons
Grants
Subscriptions
12,729
103,654
99.160
116,383
99,160
Conference fees & sponsorshlp Income
Conference income
413.049
297,904
Interest recelvable
Interest receivable
4,107
828
Total Incomlng resources
533,539
397,892
EXPENDITURE
D]rect conference costs
Annual conference costs
Annual support to UKLA
274.284
13,250
194.548
ii.soo
287,534
206.048
Othèr assoclated tonference tosls
Travel & hotels
Ath40rk/de5i8n & prlnt
CPD application
Bank charges
Website
Secretarlal support costs
E85 Costs
Partial exemption input VAT
12,511
4.216
956
5,282
4,408
2,242
3,536
4,196
6,185
5,751
175,204
170,635
116,9391
189,113
197,398
Support Costs
Governance costs
Accountancy fees
Other legal and professlonal
5,012
4.002
5,047
8,429
9,014
13,476
Total resources expended
485,661
416.922
Net Incomel{expendlture)
47,878
119,0301
Thls page does not torm part ot the statutory financlal stafements
Page 19